Мировой рынок эметогенных препаратов – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка эметогенных препаратов

Развивающиеся экономики являются основными рынками для эметогенных препаратов из-за расширения инфраструктуры здравоохранения в этих экономиках. Рост заболеваемости раком и гастроэнтеритом во всем мире, увеличение активности НИОКР и выявление нескольких новых лекарственных препаратов положительно повлияли на рост рынка. Препараты доступны в многочисленных формах, таких как внутривенные, внутримышечные и подкожные инъекции.

Data Bridge Market Research анализирует темпы роста рынка эметогенных препаратов в прогнозируемый период 2023–2030 гг. Ожидаемый среднегодовой темп роста рынка эметогенных препаратов составляет около 14,2% в указанный прогнозируемый период. Рынок оценивался в 1371,50 млн долларов США в 2022 году и вырастет до 3967,57 млн ​​долларов США к 2030 году. Помимо таких рыночных данных, как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, рыночный отчет, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки, анализ цен и нормативную базу.

Масштаб и сегментация рынка эметогенных препаратов

Market Definition

Emetogenic symptoms are associated with nausea and vomiting related to the cancer treatment such as chemotherapy, radiation therapy and drug therapy. Nausea and vomiting are the major side effects of cancer therapy. It is significant that nausea and vomiting must be controlled so the patient can continue the treatment and have a better quality of life. Majorly nausea and vomiting induced by patients on chemotherapy and radiation therapy of the brain, gastrointestinal tract, or liver also cause nausea and vomiting.

Global Emetogenic Drugs Market Dynamics

Drivers

• High Prevalence of Cancer

As per the Cancer Statistics by the National Cancer Institute, in 2020, an assessed 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease. An estimated 16,850 children and adolescents aged between 0 to 19 years were diagnosed with cancer, and 1,730 died of the same disease. Likewise, the Centers for Disease Control and Prevention reported around 179 million cases of acute gastroenteritis (AGE) occur annually in the U.S.. In the U.S. and other regions, 2-23% of children with acute gastroenteritis are treated with antiemetics, as per the reports of the American Academy of Pediatrics, 2020.

• Launch of New Drugs

Several drug launches by top market players boost the growth of the market. For instance, in September 2020, Sandoz, a Novartis division, launched generic Fosaprepitant, an anti-emetic drug used to prevent nausea and vomiting induced by chemotherapy in the U.S., increasing hospital offerings and strategically intensifying its injectables portfolio.

Opportunities

• Increased Strategic Alliances Between Market Players

There have been strategic activities such as product development, mergers, approvals, and acquisitions by major market players operating within the market are expected to boost the segment growth throughout the forecast period. For instance, in January 2022, Cumberland Pharmaceuticals, which is a specialty pharmaceutical company, acquired Sancuso, which is an oncology-supportive care medicine from Kyowa Kirin North America. Sancuso is the first and only FDA-approved Granisetron transdermal prescription patch used for the prevention of nausea and vomiting in patients who are  receiving different types of chemotherapy treatment.

• Rising Demand of Oral Drugs

Oral emetogenic drugs are crating a greater market space as they prevent or treat nausea and vomiting. They work by blocking signals from the brain to the stomach which can cause these symptoms. There are several types of drugs such as ondansetron, prochlorperazine, and metoclopramide.

Restraints/Challenges

• High Cost of Emetogenic Drugs

The huge cost associated with these drugs hamper the growth of the market. There are various drugs such as Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA combination, corticosteroids which cost quite high and thus restrict the marke growth.

This emetogenic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the emetogenic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Emetogenic Drugs Market

The COVID-19 pandemic has had a positive impact on the emetogenic drugs market. The increased cases of SARS-CoV-2 have increased the use of antiemetics to treat nausea and vomiting induced by COVID-19 or any other medication. For instance, in a study titled "Current Knowledge and recent advances in Intracellular Emetic Signaling System" published in The International Journal of Clinical Practice, 2021, it was witnessed that the use of antiemetics was majorly increased during COVID-19 to treat nausea and vomiting. It was also used in COVID-19 hospitalized patients who might be undergoing open surgery and thus more prone to nausea and vomiting. Thus, the COVID-19 outbreak positively impacted the market growth.

Recent Development

• In April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. FDA for Gimoti nasal spray. Evoke now has exclusive marketing privileges over three years from the initial approval date under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist WHICHis used as a potent antiemetic drug
• In February 2022, Acacia Pharmaceutical’s Barhemsys received US-FDA approval. It is an intravenous formulation of amisulpride for the treatment of postoperative nausea and vomiting in patients that didn’t respond to treatment with an antiemetic from a different class. The company is in commercial preparations and is expected to launch Barhemsys in the second half of 2022.

Global Emetogenic Drugs Market Scope

The emetogenic drugs market is segmented on the basis of class, types of emesis, application, drug type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

• Serotonin Receptor Antagonists (5-HT3 RAS)
• Neurokinin-1 Receptor Antagonist (NK1 RAS)
• 5HT3 RA/NK1 RA Combination
• Corticosteroids
• Olanzapine
• Others

Types of Emesis

• Acute
• Delayed
• Anticipatory
• Breakthrough
• Refractory
• Chronic
• Others

Application

• Highly Emetogenic Chemotherapy
• Moderately Emetogenic Chemotherapy
• Low Emetogenic Chemotherapy
• Other

Drug Type

• Branded
• Generic

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Emetogenic Drugs Market Regional Analysis/Insights

The emetogenic drugs market is analyzed and market size insights and trends are provided by class, types of emesis, application, drug type,  end-user and distribution channel as referenced above.

The major countries covered in the emetogenic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to increased healthcare and R&D expenditure and presence of skilled professionals

Asia-Pacific is expected to account for the largest market share due to increased prevalence of cancer and rapidly improving healthcare infrastructure in the region.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Кроме того, при предоставлении прогнозного анализа данных по странам рассматриваются наличие и доступность глобальных брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.   

Анализ конкурентной среды и доли мирового рынка эметогенных препаратов

Конкурентная среда рынка эметогенных препаратов содержит данные по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, глобальное присутствие, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование в применении. Приведенные выше данные касаются только фокуса компаний, связанного с рынком эметогенных препаратов

Ключевые игроки на рынке эметогенных препаратов:

• Heron Therapeutics, Inc. (США)
• Sandoz International GmbH (Швейцария)
• Merck & Co., Inc. (США)
• Eisai Co., Ltd (Япония)
• Teva Pharmaceutical Industries Ltd. (Израиль)
• Qilu Pharmaceutical Co., Ltd (Китай)
• F. Hoffmann-La Roche Ltd. (Швейцария)
• Mylan NV (США)
• GSK plc (Великобритания)
• Мундифарма Интернешнл (Великобритания)
• Бакстер (США)
• Bayer AG (Германия)
• Cipla Inc (США)
• Санофи. (Франция)
• Sun Pharmaceutical Industries Ltd. (Индия)

SKU-57254